These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 22175890

  • 1. Two distinct pathways of carcinogenesis in primary sclerosing cholangitis.
    Zen Y, Quaglia A, Heaton N, Rela M, Portmann B.
    Histopathology; 2011 Dec; 59(6):1100-10. PubMed ID: 22175890
    [Abstract] [Full Text] [Related]

  • 2. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma.
    Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC.
    Am J Surg Pathol; 2010 Jan; 34(1):27-34. PubMed ID: 19898228
    [Abstract] [Full Text] [Related]

  • 3. Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct--an immunohistochemical study of 110 cases of hepatolithiasis.
    Zen Y, Sasaki M, Fujii T, Chen TC, Chen MF, Yeh TS, Jan YY, Huang SF, Nimura Y, Nakanuma Y.
    J Hepatol; 2006 Feb; 44(2):350-8. PubMed ID: 16360234
    [Abstract] [Full Text] [Related]

  • 4. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence.
    Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC.
    Am J Surg Pathol; 2007 Jun; 31(6):907-13. PubMed ID: 17527079
    [Abstract] [Full Text] [Related]

  • 5. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis.
    Boberg KM, Jebsen P, Clausen OP, Foss A, Aabakken L, Schrumpf E.
    J Hepatol; 2006 Oct; 45(4):568-74. PubMed ID: 16879890
    [Abstract] [Full Text] [Related]

  • 6. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study.
    Bergquist A, Glaumann H, Persson B, Broomé U.
    Hepatology; 1998 Feb; 27(2):311-6. PubMed ID: 9462625
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis.
    Itatsu K, Zen Y, Ohira S, Ishikawa A, Sato Y, Harada K, Ikeda H, Sasaki M, Nimura Y, Nakanuma Y.
    Liver Int; 2007 Nov; 27(9):1174-84. PubMed ID: 17919228
    [Abstract] [Full Text] [Related]

  • 9. Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma.
    Barr Fritcher EG, Kipp BR, Voss JS, Clayton AC, Lindor KD, Halling KC, Gores GJ.
    Am J Gastroenterol; 2011 Nov; 106(11):2023-8. PubMed ID: 21844920
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type.
    Aishima S, Fujita N, Mano Y, Kubo Y, Tanaka Y, Taketomi A, Shirabe K, Maehara Y, Oda Y.
    Am J Surg Pathol; 2011 Apr; 35(4):590-8. PubMed ID: 21412073
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Characterization of intrahepatic cholangiocarcinoma of the intraductal growth-type and its precursor lesions.
    Yeh TS, Tseng JH, Chen TC, Liu NJ, Chiu CT, Jan YY, Chen MF.
    Hepatology; 2005 Sep; 42(3):657-64. PubMed ID: 16116640
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Biliary dysplasia in primary sclerosing cholangitis harbors cytogenetic abnormalities similar to cholangiocarcinoma.
    Kerr SE, Barr Fritcher EG, Campion MB, Voss JS, Kipp BR, Halling KC, Lewis JT.
    Hum Pathol; 2014 Sep; 45(9):1797-804. PubMed ID: 25027853
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
    Patsenker E, Wilkens L, Banz V, Osterreicher CH, Weimann R, Eisele S, Keogh A, Stroka D, Zimmermann A, Stickel F.
    J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
    [Abstract] [Full Text] [Related]

  • 20. Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma.
    Ahrendt SA, Eisenberger CF, Yip L, Rashid A, Chow JT, Pitt HA, Sidransky D.
    J Surg Res; 1999 Jun 01; 84(1):88-93. PubMed ID: 10334895
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.